In summary, the key properties of an activated uHAP that targets the hTME are as follows: (i) capacity to be delivered to the hTME,100 (ii) the selectivity for activation in hTME without significant systemic toxicity,100, 101, 102, 103, 104, 105, 106 (iii) the prolonged residence of activated prodrug at DNA sites due to high affinity for the target,135 (iv) the availability of activated drug from sequestered cellular stores,96 (v) persistent co‐location of activated uHAP within poorly vascularised tumour regions,118 (vi) the targeted long‐lived trapping of TOP2A/TOP2B ternary complexes.138. The gene discussed is TOP2A; the disease is neoplasm.